CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice

Journal of Virology

Volumn 75, Issue 14, 2001, Pages 6482-6491

  Malanchere Bres E ^a   Payette, P J ^a   Mancini, M ^a   Tiollais, P ^a   Davis, H L ^a   Michel, M L ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; OLIGODEOXYNUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; CYTOTOXICITY; HEPATITIS B VIRUS; IMMUNE RESPONSE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TRANSGENIC MOUSE; VACCINATION; VIRUS CARRIER;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; LIVER; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGODEOXYRIBONUCLEOTIDES; RNA, MESSENGER; RNA, VIRAL; VACCINATION; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES;

EID: 0034991493     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.14.6482-6491.2001     Document Type: Article

References (57)

1. Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice
2. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA
3. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections
4. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12
5. + T-cell repertoire in chronic hepatitis B virus infection
6. Hepatitis B virus immunopathogenesis
7. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice
8. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
9. Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens
10. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides
11. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells
12. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis surface antigen
13. DNA based immunization for hepatitis B induces continuous secretion of antigen and high levels of circulating antibody Hum
14. DNA vaccines
15. Inhibition of hepatitis B virus surface antigen gene expression in carcinogen-induced liver tumors from transgenic mice
16. Hepatitis B surface antigen gene expression is regulated by sex-steroids and glucocorticoids in transgenic mice
17. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes
18. Bacterial DNA induces murine interferon-gamma production by stimulation of IL-12 and tumor necrosis factor-alpha
19. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus
20. The treatment of chronic viral hepatitis
21. New therapies for chronic hepatitis B
22. The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes
23. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection
24. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma
25. Immune effects and mechanisms of action of CpG motifs
26. CpG motifs in bacterial DNA trigger direct B-cell activation
27. A one-year trial of lamivudine for chronic hepatitis B
28. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers
29. Hepatitis B virus infection
30. Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines
31. Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection
32. DNA-based immunization against the envelope proteins of the hepatitis B virus
33. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state
34. Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization
35. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates
36. Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin
37. DNA-mediated immunization to the hepatitis B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans
38. Immune response to hepatitis B virus proteins: Relevance of the murine model
39. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B
40. Immune therapy of hepatitis B virus chronic infection
41. Transcription of the S gene in transgenic mice is associated with hypomethylation at specific sites and with DNase I sensitivity
42. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein
43. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
44. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
45. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice
46. Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation
47. Similar as well as distinct MHC class I-binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen
48. Ongoing murine T1 or T2 immune responses to the hepatitis B surface antigen are excluded from the liver that expresses transgene-encoded hepatitis B surface antigen
49. Control of expression and methylation of a hepatitis B virus transgene by strain-specific modifiers
50. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device
51. Gene vaccination: Plasmid DNA is more than just a blueprint
52. Response of naïve and memory CD8+ T cells to antigen stimulation in vivo
53. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans
54. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
55. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
56. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity
57. IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides